CClinicalTrials.gg
AvailableNCT06393660Updated Oct 14, 2025

Treatment Use of the CliniMACS® CD34 TCR Alpha/Beta for Allogenic Transplant (Expanded Access Use)

An expanded access record providing CliniMACS® CD34 TCR Alpha/Beta in Transplant-Related Disorder and GVH - Graft Versus Host Reaction, sponsored by Victor Aquino. Available at 1 site in United States. Open to participants aged Up to 21 Years. Per ClinicalTrials.gov, last updated 2025-10-14.

Sponsored by Victor Aquino · Expanded access

Study type
Expanded access
Ages
Up to 21 Years
Sex
All
01

Study summary

The protocol is designed to provide access to patients to the Clinimacs® CD34 TCRαβ system to prepare cells for an unlabeled indication using an HLA-compatible related or unrelated donor for allogenic transplant.

Read the detailed description

Allogeneic hematopoietic stem cell transplant (HSCT) is the only known curative therapy for a variety of non-malignant and malignant disorders1-4. Only about 25% of patients have an HLA-matched sibling and in about 16-75% (depending on ethnicity), a 10/10 HLA-matched unrelated donor can be identified. Engraftment failure is a dynamic complex process that may occur with this product due to unbalanced depletion of T-cells between recipient and donor, not only due to low number of CD34 cells. The use of mis-matched or haploidentical donors is associated with a higher risk of post-transplant mortality due to the development of severe graft versus host disease, graft failure and the development of infection due to the use of immunosuppression or T cell depletion. A total of 10 patients will be enrolled. The patients will be divided into 2 strata (haploidentical 7, unrelated donor 3).

02

Conditions studied

  • Transplant-Related Disorder
  • GVH - Graft Versus Host Reaction

Keywords

  • TCR Alpha/Beta
  • CliniMACS
03

In context

Lead sponsor

This is the only study on the registry with Victor Aquino as lead sponsor.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
Up to 21 Years
Sexes eligible
All
Accepts healthy volunteers
No

Eligibility criteria

Recipient Inclusion Criteria:

  • Age less than 22 years of age
  • No available genotypically matched related donor (sibling)
  • Availability of a suitable donor and graft source
  • Haploidentical related mobilized peripheral blood cells
  • 9/10 or 10/10 allele matched (HLA-A, -B, -C, -DRB1, -DQB1) volunteer unrelated donor mobilized peripheral blood cells

Donor Inclusion Criteria:

  • Matching as described in the Recipient and Donor Suitability Criteria
  • Size and vascular access appropriate by center standard for peripheral blood stem cell (PBSC) collection. Donors with inadequate peripheral access will require placement of an apheresis catheter for collection.
  • Must meet appropriate screening/eligibility requirements:

    • Haploidentical matched family members: screened by center health screens and found to be eligible.
    • Unrelated donors: meet suitability criteria to donate PBSC
    • HIV negative
    • Not pregnant or lactating
    • Recipient must not have high-level donor specific anti-HLA antibodies according to institutional practices.
    • Must agree to donate PBSC
    • Must give informed consent

Recipient Suitability:

- Adequate organ functioning as demonstrated by:

  • MUGA ≥ 50% or ECHO >30%
  • 24-hour Creatinine Clearance or Glofil ≥ 50 ml/min or Serum Creatinine ≤2 times the upper limit of normal
  • DLCO > 65% of predicted value. FEV1 >65% of predicted
  • AST / ALT ≤ 2.5 and/or Bilirubin ≤ 1.5 times the upper limit of normal
  • Pregnancy test negative
  • HIV 1 / 2 (HIV screen) negative with a negative qualitative HIV PCR.
  • HTLV I negative
  • RPR or VDRL negative
  • RVP (Respiratory Viral PCR) with a negative result
  • Positive hepatitis testing does not make the patient ineligible. Hepatitis results will be evaluated on a case-by-case basis by the transplant physician to determine donor suitability/eligibility.

Donor Suitability:

- Allowed Donor Sources

  • Fully matched sibling donors are not allowed.
  • Unrelated donors. HLA typing of at least 10 alleles is required. Donor must be matched at 9/10 or 10/10 alleles (HLA-A, -B, -C, -DRB1, -DQB1). Haploidentical matched family members. Minimum match level full haploidentical (at least 5/10; HLA-A, -B, -C, -DRB1, -DQB1 alleles), but use of haploidentical donors with extra matches (e.g., 6, 7, or 8/10) encouraged.
  • Cord blood is not allowed as a stem cell source on this IDE.

Recipient and Donor Exclusion Criteria:

  • Pregnant or lactating females are ineligible as the risk to unborn children and infants is unknown
  • Presence of life-threatening, uncontrolled opportunistic infection (fungal, bacterial, or viral infections). Patients with history of fungal disease during induction therapy may proceed if they have a significant response to antifungal therapy with no or minimal evidence of disease remaining by CT evaluation.
  • HIV or HTLV I/II infection
05

Access details

Study type
Expanded access

Available treatment

  • DeviceCliniMACS® CD34 TCR Alpha/Beta

    CliniMACS System uses an automated antibody/magnetic beads column system that allows efficient depletion of TCRαβ and CD19+ cells without relevant loss of cell viability. Hematopoietic stem cells are retained in sufficient numbers to permit engraftment and hematopoietic reconstitution. Humanitarian Exemption IDE approval has been obtained for CD34+ cell selection as a method of T-cell depletion.

06

Where to request access

1 of 1 sites recruiting
07

Updates

Tracking since Sep 25, 2026
No changes since tracking began. The registry record was last updated on Oct 14, 2025, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
08

Registry details

Key details

Study ID
NCT06393660
Lead sponsor
Victor Aquino
Responsible party
Victor Aquino (Professor, University of Texas Southwestern Medical Center) — Sponsor-investigator
First posted
May 1, 2024
Last update
Oct 14, 2025

Study contacts

Victor Aquino, MD
Contact
Victor.Aquino@utsouthwestern.edu
214-648-3896
View the source record on ClinicalTrials.gov ↗

Requesting access

Expanded access is arranged between your doctor and the company. Ask your care team to contact the provider listed on this record.

Contact the provider

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion